NZ515232A - IL-8 receptor antagonists - Google Patents

IL-8 receptor antagonists

Info

Publication number
NZ515232A
NZ515232A NZ515232A NZ51523200A NZ515232A NZ 515232 A NZ515232 A NZ 515232A NZ 515232 A NZ515232 A NZ 515232A NZ 51523200 A NZ51523200 A NZ 51523200A NZ 515232 A NZ515232 A NZ 515232A
Authority
NZ
New Zealand
Prior art keywords
receptor antagonists
chemokine
interleukin
formula
treatment
Prior art date
Application number
NZ515232A
Inventor
Deborah L Bryan
John G Gleason
Katherinel Widdowson
Gregory M Benson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NZ515232A publication Critical patent/NZ515232A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention relates to novel compounds of Formula (I), pharmaceutical compositions and their use in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
NZ515232A 1999-06-16 2000-06-16 IL-8 receptor antagonists NZ515232A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16
PCT/US2000/016813 WO2000076516A1 (en) 1999-06-16 2000-06-16 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
NZ515232A true NZ515232A (en) 2004-02-27

Family

ID=22487784

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515232A NZ515232A (en) 1999-06-16 2000-06-16 IL-8 receptor antagonists

Country Status (22)

Country Link
EP (1) EP1191934A4 (en)
JP (1) JP2003501471A (en)
KR (1) KR20020009635A (en)
CN (1) CN1494424A (en)
AR (1) AR029368A1 (en)
AU (1) AU766086B2 (en)
BR (1) BR0010985A (en)
CA (1) CA2377397A1 (en)
CZ (1) CZ20014490A3 (en)
EC (2) ECSP003525A (en)
HK (1) HK1044716A1 (en)
HU (1) HUP0202019A3 (en)
IL (1) IL146214A0 (en)
MX (1) MXPA01013287A (en)
NO (1) NO20016065L (en)
NZ (1) NZ515232A (en)
PE (1) PE20010319A1 (en)
PL (1) PL352218A1 (en)
TR (1) TR200103690T2 (en)
UY (1) UY26209A1 (en)
WO (1) WO2000076516A1 (en)
ZA (1) ZA200110203B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344425B1 (en) * 1988-03-30 1993-12-08 Warner-Lambert Company N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (en) * 1996-08-15 1999-12-29 Smithkline Beecham Corp NEW COMPOUNDS CONTAINING GUANIDINE USEFUL AS ANTAGONISTS OF IL-8 RECEPTORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE FOR THE PREPARATION OF INTERMEDIARIES.

Also Published As

Publication number Publication date
AR029368A1 (en) 2003-06-25
ECSP003525A (en) 2002-01-25
UY26209A1 (en) 2000-12-29
HK1044716A1 (en) 2002-11-01
HUP0202019A2 (en) 2002-10-28
CZ20014490A3 (en) 2002-07-17
WO2000076516A1 (en) 2000-12-21
AU766086B2 (en) 2003-10-09
CA2377397A1 (en) 2000-12-21
CN1494424A (en) 2004-05-05
HUP0202019A3 (en) 2003-03-28
BR0010985A (en) 2002-03-26
PE20010319A1 (en) 2001-05-24
NO20016065D0 (en) 2001-12-12
EP1191934A1 (en) 2002-04-03
MXPA01013287A (en) 2002-06-04
ZA200110203B (en) 2002-09-11
NO20016065L (en) 2001-12-12
IL146214A0 (en) 2002-07-25
EP1191934A4 (en) 2004-02-04
PL352218A1 (en) 2003-08-11
AU5748200A (en) 2001-01-02
ECSP003528A (en) 2002-01-25
JP2003501471A (en) 2003-01-14
TR200103690T2 (en) 2002-05-21
KR20020009635A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
TR199900318T2 (en) IL-8 receptor antagonists.
BG105661A (en) Hydroxy diphenylurea sulfonamides as il-8 receptor antagonists
EP1357909A4 (en) Il-8 receptor antagonists
TR199901710T2 (en) IL-8 receptor antagonists.
EA200000299A1 (en) DRUGS
EA200300441A1 (en) ASSOCIATION OF THE ANTAGONIST OF THE RECEPTOR CB1 AND SIBUTRAMINE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION FOR THE TREATMENT OF OBESITY
ATE450508T1 (en) SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING ABILITY TO HISTAMINE H3 RECEPTORS
CY1106514T1 (en) IL-8 RECEPTOR ANTAGONISTS
ATE293448T1 (en) BENZO(D)AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS
AP2002002605A0 (en) Il-8 receptor antagonists
NZ514696A (en) IL-8 receptor antagonists
AP1548A (en) Il-8 Receptor Antagonists.
WO2005000231A3 (en) Il-8 receptor antagonists
WO2001068569A3 (en) Il-8 receptor antagonists
TR199901761T2 (en) IL-8 receptor antagonists.
AP2002002606A0 (en) IL-8 receptor antagonists.
TR200103448T2 (en) IL-8 receptor antagonists.
MY143477A (en) Il-8 receptor antagonists
WO2001076530A3 (en) Il-8 receptor antagonists
WO2000072800A3 (en) Il-8 receptor antagonists
WO2001068033A3 (en) Il-8 receptor antagonists
WO2001064165A3 (en) Il-8 receptor antagonists
BR0010863A (en) Il-8 receptor antagonists
NZ515232A (en) IL-8 receptor antagonists
WO2001068570A3 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed